D
IS
C
LA
IM
E
R
This PDF of the BMJ Best Practice topic is based on the web version that was last updated: Aug 08, 2018.
BMJ Best Practice topics are regularly updated and the most recent version
of the topics can be found on bestpractice.bmj.com . Use of this content is
subject to our disclaimer. © BMJ Publishing Group Ltd 2018. All rights reserved.
47
Contributors:
// Authors:
Daniel Boyle, MD
Instructor
Division of Infectious Diseases, Northwestern Feinberg School of Medicine, Chicago, IL
DISCLOSURES: DB declares that he has no competing interests.
Brian Wolf, MD
Infectious Diseases Fellow
Northwestern Feinberg School of Medicine, Chicago, IL
DISCLOSURES: BW declares that he has no competing interests.
// Acknowledgements:
Dr Daniel Boyle and Dr Brian Wolf would like to gratefully acknowledge Dr Teresa Zembower and Dr Pavani
Reddy, previous contributors to this topic. TZ and PR declare that they have no competing interests.
// Peer Reviewers:
Timothy Benton, MD
Regional Chairman
Residency Program Director, Associate Professor, Family and Community Medicine, Texas Tech University
Health Sciences Center at the Permian Basin, Odessa, TX
DISCLOSURES: TB declares that he has no competing interests.
Raffaele D’Amelio, MD
Professor of Internal Medicine
Director: Unit Clinical Immunology and Allergy, Department of Clinical and Molecular Medicine, Sapienza
University of Rome, S. Andrea University Hospital, Rome, Italy
DISCLOSURES: RD declares that he has no competing interests.
Ali Hassoun, MD, FACP, FIDSA, AAHIVS
Infectious Disease Specialist
Alabama Infectious Diseases Center, Huntsville, AL
DISCLOSURES: AH declares that he has no competing interests.
Tim Brooks, MA, LMSSA, MB BChir, MSc, FRCPath, FRSPH
Head of Novel & Dangerous Pathogens
Novel and Dangerous Pathogens, HPA Centre for Emergency Preparedness and Response, Salisbury, UK
DISCLOSURES: TB declares that he has no competing interests.
Dostları ilə paylaş: |